Management of neonatal abstinence syndrome from opioids

Clinics in Perinatology

Volumn 40, Issue 3, 2013, Pages 509-524

  Grim, Kendra ^a   Harrison, Tracy E ^a   Wilder, Robert T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Abstinence; Buprenorphine; Methadone; Neonatal; Opioids; Withdrawal

Indexed keywords

BUPRENORPHINE; CHLOROPROCAINE; CHLORPROMAZINE; CLONIDINE; DEXMEDETOMIDINE; DIAMORPHINE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; ONDANSETRON; OXYCODONE; PHENOBARBITAL; SEROTONIN UPTAKE INHIBITOR;

BINDING AFFINITY; BRADYCARDIA; BREAST FEEDING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONSTIPATION; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEEDING BEHAVIOR; HUMAN; HYPERTENSION; HYPOTENSION; LENGTH OF STAY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SCORING SYSTEM; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WITHDRAWAL HYPERTENSION; WITHDRAWAL SEIZURE; WITHDRAWAL SYNDROME; CHILD CARE; FOOD INTAKE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PACIFIER; PROCEDURES; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; FEEDING METHODS; HUMANS; INFANT CARE; INFANT, NEWBORN; METHADONE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PACIFIERS; TREATMENT OUTCOME;

EID: 84897117284     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2013.05.004     Document Type: Review

References (56)

1. Jansson L.M., Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012, 24(2):252-258.
2. Patrick S.W., Schumacher R.E., Benneyworth B.D., et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012, 307(18):1934-1940.
3. Ornoy A., Segal J., Bar-Hamburger R., et al. Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol 2001, 43(10):668-675.
4. Manchikanti L., Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008, 11(Suppl 2):S63-S88.
5. Campo-Flores A. Pain pills' littlest victims. The Wall Street Journal 2012, A3.
6. Jansson L.M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. JOpioid Manag 2009, 5(1):47-55.
7. Hudak M.L., Tan R.C. Neonatal drug withdrawal. Pediatrics 2012, 129(2):e540-e560.
8. Kuschel C. Managing drug withdrawal in the newborn infant. Semin Fetal Neonatal Med 2007, 12(2):127-133.
9. Seligman N.S., Salva N., Hayes E.J., et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008, 199(4):396.e1-396.e7.
10. Cleary B.J., Donnelly J., Strawbridge J., et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010, 105(12):2071-2084.
11. Seligman N.S., Almario C.V., Hayes E.J., et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. JPediatr 2010, 157(3):428-433. 433.e1.
12. Pizarro D., Habli M., Grier M., et al. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. JSubst Abuse Treat 2011, 40(3):295-298.
13. Thajam D., Atkinson D.E., Sibley C.P., et al. Is neonatal abstinence syndrome related to the amount of opiate used?. JObstet Gynecol Neonatal Nurs 2010, 39(5):503-509.
14. Dashe J.S., Sheffield J.S., Olscher D.A., et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002, 100(6):1244-1249.
15. Isemann B., Meinzen-Derr J., Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. JPerinatol 2011, 31(1):25-29.
16. Liu A.J., Jones M.P., Murray H., et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 2010, 50(3):253-258.
17. Gray T.R., Choo R.E., Concheiro M., et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction 2010, 105(12):2151-2159.
18. Oei J., Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. JPaediatr Child Health 2007, 43(1-2):9-18.
19. Ebner N., Rohrmeister K., Winklbaur B., et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007, 87(2-3):131-138.
20. Serane V.T., Kurian O. Neonatal abstinence syndrome. Indian J Pediatr 2008, 75(9):911-914.
21. Ballard J.L. Treatment of neonatal abstinence syndrome with breast milk containing methadone. JPerinat Neonatal Nurs 2002, 15(4):76-85.
22. Biswas A.K., Feldman B.L., Davis D.H., et al. Myocardial ischemia as a result of severe benzodiazepine and opioid withdrawal. Clin Toxicol 2005, 43(3):207-209.
23. Holbrook A., Kaltenbach K. Gender and NAS: does sex matter?. Drug Alcohol Depend 2010, 112(1-2):156-159.
24. Unger A., Jagsch R., Bawert A., et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?. Gend Med 2011, 8(6):355-364.
25. Olsen G.D., Lees M.H. Ventilatory response to carbon dioxide of infants following chronic prenatal methadone exposure. Journal of Pediatrics 1980, 96(6):983-989.
26. Finnegan L., Kron R., Connaughton J., et al. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975, 12:19-32.
27. Tronick E., Lester B. The NICU Network Neurobehavioral Scale: a comprehensive instrument to assess substance-exposed and high-risk infants. NIDA Res Monogr 1996, 166:198-204.
28. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEngl J Med 2010, 363(24):2320-2331.
29. Franck L.S., Harris S.K., Soetenga D.J., et al. The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med 2008, 9(6):573-580.
30. Franck L.S., Scoppettuolo L.A., Wypij D., et al. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012, 153(1):142-148.
31. Ista E., van Dijk M., de Hoog M., et al. Construction of the Sophia Observation withdrawal Symptoms-scale (SOS) for critically ill children. Intensive Care Med 2009, 35(6):1075-1081.
32. Heil S.H., Gaalema D.E., Johnston A.M., et al. Infant pupillary response to methadone administration during treatment for neonatal abstinence syndrome: a feasibility study. Drug Alcohol Depend 2012, 126(1-2):268-271.
33. Jordan A.E., Jackson G.L., Deardorff D., et al. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. JMatern Fetal Neonatal Med 2008, 21(10):745-751.
34. Langenfeld S., Birkenfeld L., Herkenrath P., et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend 2005, 77(1):31-36.
35. Velez M., Jansson L.M. The opioid dependent mother and newborn dyad: non-pharmacologic care. JAddict Med 2008, 2(3):113-120.
36. Shephard R., Greenough A., Johnson K., et al. Hyperphagia, weight gain and neonatal drug withdrawal. Acta Paediatr 2002, 91(9):951-953.
37. McQueen K.A., Murphy-Oikonen J., Gerlach K., et al. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care 2011, 11(4):282-290.
38. Ito S. Drug therapy for breast-feeding women. NEngl J Med 2000, 343(2):118-126.
39. Bogen D.L., Perel J.M., Helsel J.C., et al. Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. Breastfeed Med 2011, 6(6):377-384.
40. Wachman E.M., Byun J., Philipp B.L. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010, 5(4):159-164.
41. Arlettaz R., Kashiwagi M., Das-Kundu S., et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005, 84(2):145-150.
42. Dryden C., Young D., Campbell N., et al. Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding. Archives of disease in childhood. Arch Dis Child Fetal Neonatal Ed 2012, 97(3):F214-F216.
43. Lainwala S., Brown E.R., Weinschenk N.P., et al. Aretrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005, 5(5):265-272.
44. Kraft W.K., van den Anker J.N. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 2012, 59(5):1147-1165.
45. Kraft W.K., Dysart K., Greenspan J.S., et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011, 106(3):574-580.
46. Osborn D.A., Jeffery H.E., Cole M.J. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2005, (3). CD002053.
47. Sarkar S., Donn S.M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. JPerinatol 2006, 26(1):15-17.
48. Coyle M.G., Ferguson A., Lagasse L., et al. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. JPediatr 2002, 140(5):561-564.
49. Raol Y., Zhang G., Budreck E., et al. Long-term effects of diazepam and phenobarbital treatment during development on GABA receptors, transporters and glutamic acid decarboxylase. Neuroscience 2005, 132(2):399-407.
50. Agthe A.G., Kim G.R., Mathias K.B., et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009, 123(5):e849-e856.
51. Hoder E.L., Leckman J.F., Ehrenkranz R., et al. Clonidine in neonatal narcotic-abstinence syndrome. NEngl J Med 1981, 305(21):1284.
52. Leikin J.B., Mackendrick W.P., Maloney G.E., et al. Use of clonidine in the prevention and management of neonatal abstinence syndrome. Clin Toxicol 2009, 47(6):551-555.
53. O'Mara K., Gal P., Davanzo C. Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother 2010, 44(7-8):1342-1344.
54. McLemore G.L., Lewis T., Jones C.H., et al. Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Semin Fetal Neonatal Med 2013, 18(1):35-41.
55. Bot P., Semmekrot B.A., van der Stappen J. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. Archives of disease in childhood. Arch Dis Child Fetal Neonatal Ed 2006, 91(2):F153.
56. Zimmermann-Baer U., Notzli U., Rentsch K., et al. Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction 2010, 105(3):524-528.